SCHEMBL5728610

SCHEMBL5728610

Nc1ccc2c(c1)NC(=O)C2=Cc1ccc[nH]1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 8/20 0.80
RET P07949 5/20 0.80
FLT3 P36888 4/20 0.80
ALK Q9UM73 3/20 0.80
PDGFRB P09619 7/20 0.71
KDR P35968 5/20 0.68
CHEK1 O14757 4/20 0.68
JAK3 P52333 3/20 0.68
AURKB Q96GD4 3/20 0.68
TLK2 Q86UE8 3/20 0.68
FLT1 P17948 3/20 0.68
DAPK3 O43293 2/20 0.68
MAP4K4 O95819 2/20 0.68
NTRK1 P04629 2/20 0.68
LCK P06239 2/20 0.68
CSF1R P07333 2/20 0.68
FGFR1 P11362 2/20 0.68
LTK P29376 2/20 0.68
RPS6KA3 P51812 2/20 0.68
MAP2K1 Q02750 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728607 1.00 PDPK1 (0.80) PDPK1RETFLT3ALKPDGFRB
SCHEMBL18054 0.89 PDPK1 (1.00) PDPK1RETFLT3ALKPDGFRB
SCHEMBL18053 0.89 PDPK1 (1.00) PDPK1RETFLT3ALKPDGFRB
SCHEMBL396412 0.84 NTRK3 (0.71) PDPK1RETFLT3ALKPDGFRB
SCHEMBL396411 0.84 NTRK3 (0.71) PDPK1RETFLT3ALKPDGFRB
SCHEMBL10091848 0.84 NTRK3 (0.71) PDPK1RETFLT3ALKPDGFRB
SCHEMBL5728403 0.83 PDGFRB (0.80) PDPK1RETFLT3ALKPDGFRB
SCHEMBL396431 0.83 PDGFRB (0.71) PDPK1RETFLT3ALKPDGFRB
SCHEMBL396432 0.83 PDGFRB (0.71) PDPK1RETFLT3ALKPDGFRB
SCHEMBL5728402 0.83 PDGFRB (0.80) PDPK1RETFLT3ALKPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680401-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER Schering Aktiengesellschaft (DE) 2006-07-19 EP claimed
WO-2005040116-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER SCHERING AKTIENGESELLSCHAFT (DE) 2005-05-06 WO claimed
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-28 US claimed
US-7105563-B2 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2006-09-12 US disclosed
EP-1680401-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER Schering Aktiengesellschaft (DE) 2006-07-19 EP disclosed
WO-2005040116-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER SCHERING AKTIENGESELLSCHAFT (DE) 2005-05-06 WO disclosed
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer PDK3, PDK2, PDK4 PDPK1 4/4885RET 1754/4885FLT3 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.